Mechanisms of Dexamethasone-Mediated Inhibition of Toll-Like Receptor Signaling Induced by Neisseria meningitidis and Streptococcus pneumoniae

Trine H. Mogensen,1* Randi S. Berg,1,2 Søren R. Paludan,2 and Lars Østergaard1

Department of Infectious Diseases, Skejby Hospital, Aarhus, Denmark,1 and Institute of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark2

Received 21 June 2007/Returned for modification 29 July 2007/Accepted 6 October 2007

Excessive inflammation contributes to the pathogenesis of bacterial meningitis, which remains a serious disease despite treatment with antibiotics. Therefore, anti-inflammatory drugs have important therapeutic potential, and clinical trials have revealed that early treatment with dexamethasone significantly reduces mortality and morbidity from bacterial meningitis. Here we investigate the molecular mechanisms behind the inhibitory effect of dexamethasone upon the inflammatory responses evoked by Neisseria meningitidis and Streptococcus pneumoniae, two of the major causes of bacterial meningitis. The inflammatory cytokine response was dependent on Toll-like receptor signaling and was strongly inhibited by dexamethasone. Activation of the NF-κB pathway was targeted at several levels, including inhibition of IκB phosphorylation and NF-κB DNA-binding activity as well as upregulation of IκBα synthesis. Our data also revealed that the timing of steroid treatment relative to infection was important for achieving strong inhibition, particularly in response to S. pneumoniae. Altogether, we describe important targets of dexamethasone in the inflammatory responses evoked by N. meningitidis and S. pneumoniae, which may contribute to our understanding of the clinical effect and the importance of timing with respect to corticosteroid treatment during bacterial meningitis.

Bacterial meningitis is a severe acute infectious disease which remains a serious condition, with considerable mortality and morbidity worldwide. Among the most frequent causes of bacterial meningitis are Streptococcus pneumoniae and Neisseria meningitidis. It has been well established for decades that immunopathology, i.e., the exaggerated activation of the host's immune response induced by bacteria or their products, plays a major role in the pathogenesis of bacterial infection in the central nervous system (9). This view is underscored by the fact that mortality from bacterial meningitis, and from pneumococcal meningitis in particular, has not declined significantly for many years, even in the presence of appropriate antibiotic treatment. Large clinical trials have demonstrated that early treatment with glucocorticoids significantly reduces mortality and morbidity from bacterial meningitis in children and, as more recent reports have demonstrated, also in adults (11, 33, 40, 44). These results have led to the recommendation of introducing adjuvant glucocorticoids together with antibiotics for the early treatment of bacterial meningitis (44).

When pathogens enter the central nervous system, they replicate and, in this process, expose microbial material to host cells, which subsequently trigger an inflammatory response. This response is mediated by cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-6, IL-8, and prostaglandins produced by macrophage-equivalent brain cells, including astrocytes and microglia, as well as cerebral capillary endothelial cells (13, 40). The resultant leukocyte recruitment, meningeal inflammation, and increased permeability of the blood-brain barrier, if not orchestrated and regulated tightly, may cause cerebral edema, increased intracranial pressure, and neuronal injury (9).

The innate inflammatory immune response is of crucial importance for the early containment of infection but, at the same time, has the potential to result in immunopathology. The final outcome of infection therefore depends on an intricate balance between the pathogen and the host response. One of the central components of the innate immune system is the family of Toll-like receptors (TLRs). These pattern recognition receptors recognize evolutionarily conserved pathogen-associated molecular patterns present on most types of microorganisms (19). Once TLRs are activated, they signal to the host the presence of infection and trigger signaling cascades leading to antimicrobial and inflammatory responses involving both innate and adaptive immunity (19).

TLR ligand engagement results in intracellular signal transduction, including activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinases (MAPKs). The TLR-activated signaling pathways proceed through adaptor proteins (most importantly MyD88) and lead to activation of the MAPKs and the inhibitory IκB (IκB) protein kinase (IKK) complex. IKK in turn phosphorylates IκB and targets it for degradation, hence liberating NF-κB, which migrates to the nucleus and activates transcription of target genes (2, 12, 20, 35, 42).

Glucocorticoids are widely used due to their potent anti-inflammatory and immunosuppressive effects. However, the molecular mechanisms behind these effects are very complex and still not fully understood, although several targets have been identified. Since glucocorticoids are known to interfere with many signaling pathways and molecules involved in TLR

* Corresponding author. Mailing address: Department of Infectious Diseases, Skejby Hospital, Bredstrupgadevej, DK-8200 Aarhus N, Denmark. Phone: 45 89498499. Fax: 45 89498310. E-mail: trine.mogensen@dadlnet.dk.

† Published ahead of print on 15 October 2007.
signaling, it has been hypothesized that TLR signaling pathways may be important targets for glucocorticoid action and may explain many of their anti-inflammatory and immunosuppressive effects (32). A number of levels at which glucocorticoids can exert their multiple anti-inflammatory effects have been identified, including direct interaction with the transcriptional machinery, interference with upstream signal transduction, and modulation of RNA stability (32). Briefly, glucocorticoids bind specifically to the intracellular glucocorticoid receptor α, thereby promoting dissociation from heat shock protein 90 and subsequent translocation to the nucleus, where this ligand-activated transcription factor can activate the expression of genes with anti-inflammatory effects, including lipocortin, IL-1 receptor antagonist, IL-10, and IkB genes (1, 4), through binding to glucocorticoid response elements (6). Another major anti-inflammatory mechanism is glucocorticoid-mediated repression of a whole array of genes encoding proinflammatory mediators, such as cytokines, chemokines, and leukocyte adhesion molecules (32). This effect is mainly achieved through direct protein-protein interactions between the glucocorticoid-glucocorticoid receptor complex and the transcription factors NF-κB and AP-1, thereby reducing or preventing interaction with the essential coactivator CBP/p300, resulting in inhibition of their transactivating potential. At the level of signal transduction, glucocorticoids can inhibit upstream proinflammatory signaling through both the NF-κB and MAPK pathways (32). Dexamethasone has been demonstrated to inhibit activation of the MAPKs extracellular signal-regulated kinase 1/2 (ERK1/2), Jun N-terminal kinase (JNK), and p38 by a mechanism involving upregulation and decreased degradation of MAPK phosphatase 1, thereby preventing phosphorylation and activation of these MAPKs (8, 15, 25, 43), and the NF-κB pathway seems also to be targeted at a level upstream of IkB degradation (45).

Here we investigate the effect and mechanism of action of dexamethasone on the inflammatory responses evoked by N. meningitidis and S. pneumoniae, two of the main causes of bacterial meningitis.

MATERIALS AND METHODS

Cell culture. Peripheral blood mononuclear cells (PBMCs) were isolated from blood obtained from healthy adult donors by Isopaque-Ficoll separation. The cells stably contain a reporter system where chloramphenicol acetyltransferase (CAT) mRNA is expressed constitutively. In one of the cell lines, the 3′ UTR of the CAT-encoding mRNA was taken from wild-type NF-κB (RAW TNF-α 3′ UTR AU−) +, whereas in the other cell line, the 3′ UTR was again taken from TNF-α, but the AU-rich region (AUR) was mutated (RAW TNF-α 3′ UTR AU+). The idea is that any observed differences in CAT protein levels can be ascribed to the AUR in the 3′ UTR, which is a major regulator of mRNA stability (22).

Bacteria and reagents. The bacteria used were the N. meningitidis strain NG903 and the S. pneumoniae strain SK1013. The bacteria were grown overnight in brain heart infusion broth with 10% Levinthal broth (Statens Serum Institut, Copenhagen, Denmark) reaching a concentration of 1.8 × 10⁷ ± 2.2 × 10⁶ bacteria per ml, as determined in a Thoma counting chamber. Pamp,CSKα, lipopolysaccharide (LPS; ultrapure from Escherichia coli O111:B4), and oligo deoxynucleotide (ODN) M362 were all obtained from Invivogen (San Diego, CA). TNF-α was purchased from R&D Systems. The MyD88 homo-2}

Downloaded from http://iai.asm.org/ on September 7, 2017 by guest
(cytokine assay) or overnight at 4°C (phosphoprotein assay). After a wash step, a detection antibody was added to each well, and the plate was shaken (300 rpm) and incubated at room temperature in the dark for 45 min to 2 h (cytokine and phosphoprotein assays). Subsequently, the plate was washed and cytokine levels were measured by Luminex technology. (E and F) PBMCs and THP-1 cells were treated with dexamethasone at doses from 1 nM to 1.0 μM 1 h prior to stimulation with 9 × 10⁷ bacteria/ml of N. meningitidis or S. pneumoniae or with LPS (100 ng/ml). Twenty hours later, supernatants were harvested and cytokine levels were measured by Luminex technology. The data are shown as means for triplicate cultures ± SEM. (G) Total RNA was harvested from THP-1 cells pretreated with dexamethasone (1 μM) for 1 h and treated with bacteria (9 × 10⁷ bacteria/ml) for 5 h. IL-8 and β-actin mRNAs were detected by RT-PCR. Similar results were obtained in two or three independent experiments. UT, untreated cells.

**RESULTS**

**Dexamethasone inhibits IL-8 production induced by N. meningitidis and S. pneumoniae.** In human PBMCs, N. meningitidis and S. pneumoniae trigger a potent inflammatory response involving several cytokines and chemokines (30). In an initial set of experiments, we examined the ability of the two bacterial species to induce the expression of cytokines. PBMCs were treated with increasing doses of N. meningitidis and S. pneumoniae, and accumulation of IL-8 in the culture supernatants was measured. Both bacteria strongly induced expression of the cytokine, with N. meningitidis being slightly more potent (Fig. 1A). In order to investigate the effect of dexamethasone on proinflammatory cytokine production induced in the presence of these bacteria, PBMCs were seeded and treated as described above for the appropriate amount of time. For cell lysis and measurement of CAT levels, a CAT ELISA kit from Roche (Basel, Switzerland) was used.

**FIG. 1.** Dexamethasone inhibits induction of proinflammatory cytokines by N. meningitidis and S. pneumoniae. (A) PBMCs were seeded and treated for 20 h with N. meningitidis or S. pneumoniae at increasing doses, from 9 × 10⁵ bacteria/ml to 9 × 10⁷ bacteria/ml. Supernatants were harvested, and IL-8 levels were measured by Luminex technology. (B to D) PBMCs were treated with 1 μM dexamethasone 1 h before stimulation of the cells with LPS (100 ng/ml), Pam3Csk4 (200 ng/ml), ODN M362 (1 μM), or 9 × 10⁷ bacteria/ml of N. meningitidis or S. pneumoniae (S.p.). Twenty hours later, supernatants were harvested and cytokine levels were measured by Luminex technology. (E and F) PBMCs and THP-1 cells were treated with dexamethasone at doses from 1 nM to 1.0 μM 1 h prior to stimulation with 9 × 10⁷ bacteria/ml of N. meningitidis or S. pneumoniae or with LPS (100 ng/ml). Twenty hours later, supernatants were harvested and cytokine levels were measured by Luminex technology. The data are shown as means for triplicate cultures ± SEM. (G) Total RNA was harvested from THP-1 cells pretreated with dexamethasone (1 μM) for 1 h and treated with bacteria (9 × 10⁷ bacteria/ml) for 5 h. IL-8 and β-actin mRNAs were detected by RT-PCR. Similar results were obtained in two or three independent experiments. UT, untreated cells.
TLR9, whereas *S. pneumoniae* inginitis and found that investigated the pattern of TLR activation by bacteria causing meningitis through a TLR-dependent mechanism.

Cytokine, although it exerted a less pronounced effect on cells and found that dexamethasone inhibited expression of the /H9262. Finally, we examined IL-8 mRNA expression in THP-1 dexamethasone was present at concentrations from 10 nM to 1 M. For *S. pneumoniae* potent infection was TLR dependent. To test this, we inhibited TLR signal-NGONEN ET AL. INFECT. IMMUN.

The data are shown as means for triplicate cultures ± SEM. Similar results were obtained in two to four independent experiments.

**FIG. 2.** *N. meningitidis* and *S. pneumoniae* induce inflammatory cytokine expression through TLRs. PBMCs (A) or THP-1 cells (B) were seeded and treated with control peptide (Con pep.) or MyD88 inhibitory peptide (100 μM; MyD88 pep.) for 24 h before stimulation for 20 h with 9 × 10^7 bacteria/ml of *N. meningitidis* (N.m.), or *S. pneumoniae* (S.p.), 100 ng/ml of LPS, or 25 ng/ml of TNF-α. Levels of IL-8 in the supernatants were measured by Luminex technology. The data are shown as means for triplicate cultures ± SEM. Similar results were obtained in two to four independent experiments.

**FIG. 3.** *N. meningitidis* and *S. pneumoniae* display differential sensitivity to timing of dexamethasone treatment with respect to induction of cytokine expression. PBMCs (A) or THP-1 cells (B) were treated with 1.0 μM of dexamethasone at the indicated time points before stimulation with 9 × 10^7 bacteria/ml of *N. meningitidis* (N.m.) or *S. pneumoniae* (S.p.). At 20 h poststimulation, supernatants were harvested and levels of IL-8 were determined. The data are shown as means for triplicate cultures ± SEM. Similar results were obtained in two to four independent experiments.

effects of the steroid, as assessed by trypan blue staining (data not shown), and was also specific, since the ability of alpha interferon to phosphorylate STAT2 was not modified by pretreatment with dexamethasone (data not shown).

Next, we preincubated PBMCs and the human monocytic cell line THP-1 with different doses of dexamethasone 30 min before the addition of *N. meningitidis* and *S. pneumoniae*. After 20 h of incubation, the supernatants were analyzed for IL-8. As shown in Fig. 1E and F, both *N. meningitidis* and *S. pneumoniae* induced large amounts of IL-8, which was inhibited in a dose-dependent manner by dexamethasone. For *N. meningitidis* and LPS, the cytokine response was inhibited significantly by all concentrations of dexamethasone used (1 nM to 1 μM), whereas for *S. pneumoniae* significant inhibition was seen when dexamethasone was present at concentrations from 10 nM to 1 μM. Finally, we examined IL-8 mRNA expression in THP-1 cells and found that dexamethasone inhibited expression of the cytokine, although it exerted a less pronounced effect on *S. pneumoniae*-induced IL-8 than on that induced by *N. meningitidis* (Fig. 1G).

*N. meningitidis* and *S. pneumoniae* induce cytokine expression through a TLR-dependent mechanism. We previously investigated the pattern of TLR activation by bacteria causing meningitis and found that *N. meningitidis* activates TLR2, TLR4, and TLR9, whereas *S. pneumoniae* activates TLR2 and TLR9 (30). Therefore, we hypothesized that bacterially induced IL-8 production was TLR dependent. To test this, we inhibited TLR signaling, using a cell-permeable MyD88 inhibitory peptide or a control peptide. MyD88 exists as a homodimer when recruited to activated TLRs. The inhibitor peptide contains a sequence from the MyD88 TIR homodimerization domain. MyD88 monomers bind to this inhibitor peptide, thereby blocking MyD88 homodimerization. The cells were treated with the peptide 24 h prior to stimulation, and supernatants were harvested at 20 h poststimulation for measurement of IL-8. As shown in Fig. 2, the ability of both *N. meningitidis* and *S. pneumoniae* to induce IL-8 production was strongly inhibited in the presence of the MyD88 inhibitory peptide in both PBMCs (Fig. 2A) and THP-1 cells (Fig. 2B). The specificity of the MyD88 inhibitory peptide was shown by its ability to inhibit IL-8 induction by LPS but not by TNF-α, the latter of which signals independently of TLRs and MyD88 (26). Thus, the two bacteria induced cytokine expression largely through a TLR-dependent mechanism.

**Kinetics of dexamethasone-mediated inhibition of TLR signaling.** In clinical trials of dexamethasone treatment of patients with bacterial meningitis, timing has proved to be important for achievement of significant clinical effects (11). In order to examine if the action of dexamethasone was also dependent on the time of addition relative to the addition of bacteria in our cell culture system and to gain further insight into the mechanism of action of glucocorticoids, we examined the consequences of dexamethasone added prior to, concomitant with, or following stimulation of PBMCs or THP-1 cells with relevant bacteria (Fig. 3). *N. meningitidis* potently induced IL-8 in both cellular systems, and this response was completely abrogated when dexamethasone was added 2 h prior to or concomitant with bacteria and partially inhibited when the steroid was added at later time points. The inhibition was highly significant even when dexamethasone was added at 7 h postinfection. *S. pneumoniae*-induced IL-8 production was strongly inhibited when dexamethasone was added between 2 h and 3 h poststimulation.
before and 2 h after the bacteria were added. However, in contrast to the pattern observed with *N. meningitidis*, dexamethasone was no longer able to mediate significant inhibition of IL-8 production if it was added at later time points. These results indicate that in the case of *N. meningitidis*, dexamethasone seems to have a maximal effect when it can interfere with signaling at early time points but also has some potency when included several hours after bacterial infection. With respect to *S. pneumoniae*, dexamethasone similarly works at early time points, fully inhibiting the IL-8 response, but does not have any effect when added later than 2 h after treatment with bacteria.

**Dexamethasone inhibits *N. meningitidis* and *S. pneumoniae*-induced TLR signaling by interfering with upstream signal transduction.** The data described above strongly suggested that dexamethasone interferes with the bacterium-induced proinflammatory response at an upstream level relatively soon after bacterial challenge. Glucocorticoids are known to interfere with several signaling pathways at different levels (1, 5, 7, 17, 37, 43). In subsequent experiments, we focused on the transcription factor NF-κB, which we reasoned may be activated by these bacteria and also could represent relevant targets for dexamethasone action. THP-1 cells pretreated with dexamethasone for 2 h were incubated for 2 h in the presence of *N. meningitidis* or *S. pneumoniae*, and whole-cell extracts were isolated and analyzed by Luminex technology to determine the levels of total and phosphorylated IkBα. As shown in Fig. 4A, *N. meningitidis* and *S. pneumoniae* induced three- to fourfold increases in IkBα phosphorylation. Although dexamethasone significantly inhibited the responses induced by both bacteria, it exerted the strongest effect on *N. meningitidis*-induced IkBα phosphorylation. Following IkBα phosphorylation, the inhibitory protein is ubiquitinated and degraded by the proteasome pathway. Accordingly, total levels of IkBα in cells decreased in response to treatment with bacteria or LPS (Fig. 4B), and this was largely prevented if cells had been pretreated with dexamethasone. Interestingly, we also observed that dexamethasone treatment alone led to a significant and reproducible induction of IkBα mRNA and protein (Fig. 4B and C). The final steps in NF-κB activation are translocation to the nucleus, binding to specific sites in gene promoters, and activation of NF-κB-driven gene transcription. To investigate the effect of dexamethasone on the DNA-binding activity of NF-κB, we also harvested nuclear extracts from cells pretreated with dexamethasone and stimulated with bacteria for 2 h and subsequently measured DNA binding of the NF-κB subunit p65. As shown in Fig. 4D, both bacterial species induced the DNA-binding activity of p65, and as seen at the level of P-IkBα, dexamethasone inhibited *S. pneumoniae* p65 DNA binding less efficiently than that of *N. meningitidis*.

Taken together, the two different bacteria induced IkB phosphorylation followed by IkB degradation and NF-κB activation, and dexamethasone inhibited *N. meningitidis*-induced signaling more potently than that induced by *S. pneumoniae*, as already observed at the level of IL-8 mRNA synthesis (Fig. 1G).

**Effect of dexamethasone on bacterially induced cytokine production is independent of de novo protein synthesis.** The findings above suggested that dexamethasone inhibits signaling to NF-κB both by inducing synthesis of IkBα and by preventing phosphorylation of this inhibitory protein. To examine if inhibition of IkBα phosphorylation was dependent on de novo protein synthesis or if dexamethasone was mediating this function independently of its activity as a transcription factor, we treated cells with the protein synthesis inhibitor cycloheximide and subsequently added dexamethasone, followed by bacteria or LPS. Total cell lysates were isolated after 2 h of incubation with bacteria, and the levels of phosphorylated IkBα were determined. As also shown in Fig. 4A, we found that *N. meningitidis*, *S. pneumoniae*, and LPS all induced IkBα phosphorylation, which was significantly inhibited by dexamethasone (Fig. 5). Importantly, the ability of dexamethasone to prevent phosphorylation of IkBα was also observed in cells treated with cycloheximide, thus suggesting that dexamethasone exerted...
FIG. 5. Dexamethasone inhibits cellular signaling induced by bacteria, independent of de novo protein synthesis. THP-1 cells were treated with cycloheximide (20 μg/ml, CHX) 30 min before receiving 1.0 μM of dexamethasone. One hour later, the cells were stimulated with 9 × 10^7 bacteria/ml of N. meningitidis (N.m.) or S. pneumoniae (S.p.) for 2 h, and whole-cell extracts were isolated. Phosphorylation of IκBα was measured by Luminex technology. The data are shown as means for duplicate cultures ± SEM. Similar results were obtained in two independent experiments.

FIG. 6. TNF-α mRNA stability is increased by N. meningitidis and S. pneumoniae through an AUR-dependent mechanism, which is not affected by dexamethasone. RAW TNF-α 3' UTR AU+ and RAW TNF-α 3' UTR AU− cells were seeded and left for 4 h before the addition of 1 μM dexamethasone. Two hours later, 9 × 10^7 bacteria/ml of N. meningitidis (N.m.) or S. pneumoniae (S.p.) were added to the cells as indicated. Twenty hours later, the cells were lysed and CAT levels were measured by ELISA. The data are shown as means ± SEM. Similar results were obtained in three independent experiments.

this function independently of the induction of de novo protein synthesis.

**Bacterial infection enhances mRNA stability, which is not affected by dexamethasone.** In addition to being regulated at the transcriptional level, many proinflammatory mediators are regulated at the level of mRNA stability through AURs in the 3' UTR of the mRNA (22). We wanted to examine if the ability of S. pneumoniae and N. meningitidis to stimulate expression of proinflammatory cytokines involves stabilization of mRNA and if this is counteracted by glucocorticoids. For this purpose, we used a previously reported system with two cell lines derived from the macrophage-like cell line RAW264.7 (16, 36, 46). These cells were treated with dexamethasone 2 h prior to incubation with bacteria, and cellular lysates were prepared at 20 h postinfection. As shown in Fig. 6, the addition of either bacterium led to an increase in the levels of CAT, with S. pneumoniae being far more potent than N. meningitidis. The ability of bacteria to stabilize TNF-α mRNA was largely AUR dependent, although a minor stabilizing activity of S. pneumoniae remained in the RAW TNF-α 3' UTR AU− cells. Importantly, dexamethasone did not affect CAT expression, regardless of which other stimuli were given. In separate experiments, we found that dexamethasone did work in the cellular system used, since LPS-induced expression of IL-6 and TNF-α was strongly inhibited (data not shown). Thus, N. meningitidis and, in particular, S. pneumoniae trigger AUR-dependent stabilization of mRNAs, and this activity is not counteracted by dexamethasone.

**DISCUSSION**

The molecular mechanisms of dexamethasone action have been studied extensively, and dexamethasone is known to interfere with proinflammatory signal transduction, gene expression, and protein synthesis at various levels (32). However, the precise targets of dexamethasone with respect to TLR-mediated signaling and cytokine production are less well defined. Since dexamethasone is widely used clinically to inhibit or dampen inflammation, whether it is triggered by infectious microorganisms or autoimmunity, and since TLRs play important roles in inducing such inflammation, we were interested in studying the molecular targets of dexamethasone-mediated inhibition of inflammation triggered by TLRs. In this study, we therefore investigated how dexamethasone inhibits proinflammatory signaling induced by live N. meningitidis and S. pneumoniae, two leading causes of bacterial meningitis, as large clinical trials have demonstrated the beneficial effect of early treatment with dexamethasone (11).

It has been proposed that TLR signaling pathways are key targets for the anti-inflammatory and immunosuppressive effects of glucocorticoids (32, 34, 35). Furthermore, LPS-induced inflammation has been demonstrated to be inhibited by glucocorticoids (27). We and others have previously demonstrated that S. pneumoniae activates TLRs 2 and 9 (3, 30, 47), whereas N. meningitidis signals through TLRs 2, 4, and 9 (18, 28, 30, 48). In our experimental system, we found that the vast majority of IL-8 produced in the presence of bacteria could be inhibited when TLR signaling through MyD88 was blocked. Therefore, the bacterially induced cytokine production observed was largely mediated through TLRs. However, we cannot formally exclude that the residual IL-8 measured in the presence of the MyD88 inhibitor may be due to TLR-independent pathways activated by the bacteria, which has indeed been described for S. pneumoniae (23). The nature of potential TLR-independent (or at least MyD88-independent) signaling mechanisms triggered by bacteria remains unknown.

Aiming at understanding the molecular targets of dexamethasone in bacterially induced, TLR-mediated proinflammatory signaling, we studied the diverse levels upon which dexamethasone might potentially act. First, we found that both IκBα phosphorylation and degradation as well as NF-κB DNA-binding activity were potently inhibited by dexamethasone. The finding that IκBα phosphorylation was affected strongly sug-
gests a target upstream of this molecule. This might be IKK as well as other kinases or adaptor molecules involved in upstream TLR-mediated signaling (21). A previously described mechanism of direct interaction of glucocorticoids with p65 may also be involved (1), but our experimental setup does not allow us to determine the relative contributions of direct p65 inhibition and inhibition of IkB phosphorylation. Furthermore, we identified a separate mechanism by which dexamethasone itself induced increases in the levels of total cellular IkBα mRNA and protein, which ultimately may result in binding and inhibition of free transcriptionally active nuclear or cytoplasmic p65. For different experimental systems, similar mechanisms have been reported, including glucocorticoid-induced IkBα synthesis and upregulation of IkBα mRNA expression in the brain (5, 37). Finally, we observed that regardless of whether IkBα phosphorylation, NF-κB DNA binding, or IL-8 production was measured, dexamethasone seemed to exert a more powerful effect on *N. meningitidis*-induced activities than on those triggered by *S. pneumoniae*.

JNK and p38, both belonging to the family of MAPKs, are prominent targets of dexamethasone as well (7, 17, 41, 43), but since the THP-1 cell line did not activate the MAPKs in response to either *N. meningitidis* or *S. pneumoniae*, the question of a possible effect of dexamethasone on these MAPKs could not be addressed.

Our data on the kinetics of dexamethasone-mediated inhibition of cytokine production provide some additional insights into the mechanisms of action of dexamethasone. First, there may be several different mechanisms operating for dexamethasone-mediated inhibition of *N. meningitidis*-induced IL-8 production, since the response was fully inhibited when dexamethasone was added prior to or concomitant with bacteria and only partially inhibited at later time points. These results may be explained by the existence of an early mechanism, involving inhibition of upstream signaling as demonstrated, including inhibition of IkBα phosphorylation and NF-κB DNA-binding activity, where the presence of dexamethasone is required before or at least concomitant with bacterial challenge, and a late mechanism, possibly involving induction or upregulation of other cellular factors. The latter mechanism may be dependent upon de novo protein synthesis. For instance, Imasato et al. demonstrated that *Haemophilus influenzae*-induced upregulation of TLR2 was enhanced by dexamethasone by a mechanism involving upregulation of MKP-1, which in turn results in dephosphorylation and inactivation of p38 (17). However, in our experimental system, the inhibitory action of dexamethasone upon IkBα phosphorylation did not seem to be dependent upon protein synthesis.

As suggested by our data, different inhibitory mechanisms may exist, depending on whether inflammatory signaling is induced by *N. meningitidis* or *S. pneumoniae*. Both bacteria have in common that dexamethasone must be present before or concomitant with bacterial challenge in order to have the maximum effect, but we observed a clear difference with respect to the effect at later time points, where dexamethasone could partially inhibit IL-8 induced by meningococci, in contrast to the absence of any inhibitory effect exerted upon IL-8 induced by pneumococci. This idea is further supported by our previous finding that *N. meningitidis* and *S. pneumoniae* use distinct yet overlapping sets of TLRs, and possibly TLR-independent signaling as well (30). Taken together, looking at IkBα phosphorylation, NF-κB DNA-binding activity, and IL-8 production, there is a tendency towards dexamethasone inhibiting *S. pneumoniae*-induced inflammation to a lesser degree than that for inflammation induced by *N. meningitidis*.

In addition to regulation at the level of transcription, control of mRNA stability also represents an important level of regulation of inflammatory gene expression (22). AURs in the 3′ UTRs of mRNAs are targeted by specific constitutive and stimulus-regulated RNA-binding proteins capable of either stabilizing or destabilizing the mRNA (10, 22). We found that both *N. meningitidis* and *S. pneumoniae* stabilized TNF-α mRNA in an AUR-dependent manner, with *S. pneumoniae* being a particularly potent activator of this response. While it has long been known that purified and synthetic TLR ligands can stabilize mRNA through AUR elements (16, 38, 39), to our knowledge this is the first report showing how live *N. meningitidis* and *S. pneumoniae* interact with this important step in the inflammatory response. Although glucocorticoids have been reported to destabilize mRNAs for cyclooxygenase 2, monocyte chemoattractant protein 1, and inducible NO synthase (24, 25, 39), we did not observe any effect of steroid treatment on TNF-α mRNA stability, despite all these mRNAs being regulated by AURs in the 3′ UTR. This could indicate that dexamethasone utilizes a mechanism that is not yet well characterized to destabilize only a subset of transcripts bearing the AUR signature.

In a large randomized clinical trial of dexamethasone treatment of adults with bacterial meningitis, timing has proved to be an important issue, since mortality and morbidity were reduced only when dexamethasone was given prior to or concomitant with the initiation of antibiotic treatment (11). Furthermore, subgroup analysis indicated that dexamethasone may be particularly effective for patients with pneumococcal meningitis (11, 29). In this study, we have identified some of the cellular targets of dexamethasone in inflammatory signaling induced by *N. meningitidis* and *S. pneumoniae* and, more specifically, addressed the questions regarding the importance of timing and the possible more important effect upon pneumococcal meningitis.

Pneumococcal meningitis has the poorer prognosis with regards to mortality and also carries a relatively great risk of acquiring permanent sequelae. This may be due to the more overwhelming nature of the *S. pneumoniae*-induced inflammatory response, which even increases early after antibiotic treatment, since penicillin enhances bacterial lysis mediated by pneumococcal autolysin, hence liberating bacterial cell wall components and DNA (14, 31), which activate TLRs and elicit strong signals for enhanced inflammation. Similar mechanisms may also be operating during meningococcal meningitis, although to a lesser extent. Therefore, the early presence of dexamethasone is required in order to prevent excessive inflammation, and this may be particularly important during pneumococcal meningitis, for which our data indicate that dexamethasone is indeed effective only at early time points. Taken together, our results suggest that dexamethasone must be given early to patients with bacterial meningitis in order to inhibit TLR-dependent proinflammatory signaling and gene expression, including inhibition at various levels of the transcription factor NF-κB, as demonstrated in this study.
ACKNOWLEDGMENTS

This work was supported by grants from the LEO Pharma Research Foundation, Kong Christian den Tiendes Fond, Beckett Fonden, and The Danish Medical Research Council (grant 271-06/0438).

We thank Mogens Kilián for a critical reading of the manuscript and invaluable discussions, as well as technicians Jonna Guldborg, Tove Findahl, and Kirsten Stadel Pedersen for excellent assistance.

REFERENCES


7. MDP and LPS synergize to activate TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem. 279:38314–38319.


